MicroRNAs and Target Genes in Pituitary Adenomas

Ying Feng,Zhi-gang Mao,Li Wang,Qiu Du,Mengyao Jian,Dimin Zhu,Zheng Xiao,Haijun Wang,Yonghong ZHU

DOI: https://doi.org/10.1055/a-0585-7410

2018-01-01

Hormone and Metabolic Research

Abstract:Yajuan Feng, Zhi-gang Mao, Xin Wang, Qiu Du, Mengyao Jian, Dimin Zhu, Zheng Xiao, Hai-jun Wang, Yong-hong Zhu

What problem does this paper attempt to address?

IsolationThe role of microRNA in the diagnosis and treatment of pituitary adenomas

Tyh WONG,Ye GU,Yu-ying HUANG,Xiao-biao ZHANG

2016-01-01

Abstract:MicroRNAs (miRNAs) are small non-coding RNAs involved in the expression and regulation after target gene transcription .Through complete or incomplete pairing with corresponding target gene so as to degrade mRNA or interfere with its translation ,they negatively regulate target gene expression .The differential expression of miRNA has been reported to play a role in the pathophysiological process of neoplastic and non-neoplastic diseases .Pituitary adenomas are tumors that occur in the anterior pituitary gland .Recently ,researchers have found that differential expression of miRNA can be shown in different hormone types ,sizes and invasiveness of pituitary adenoma and pituitary carcinoma ,which implicate the possible role of miRNA as diagnosis marker and therapeutic target of pituitary adenoma .This article will summarize the research progress of miRNA in the diagnosis and treatment of pituitary adenomas .
Enhanced EPR Effects by Tumour Stromal Cell Mimicking Nanoplatform on Invasive Pituitary Adenoma

Junning Ma,Wei Yin,Xiaojian Zhang,Lu Lin,Youmei Bao,Lisi Dai,Hui Cao,Honghwei Chen,Jianbo Yu,Jiqi Yang,Yue Zhang,Huimin Lan,Xueyang Li,Qiong Huang,Dan Yang,Yajun Yu,Jingyao Chen,Chengchen Zhang,Li Liu,Chen Lei,Renya Zhan,Fei Liu

DOI: https://doi.org/10.1016/j.mtbio.2023.100895

IF: 8.2

2024-01-01

Materials Today Bio

Abstract:Rapid advances in nanomedicine have enabled potential applications in cancer therapy. The enhanced permeability and retention (EPR) effect is the primary rationale for the passive targeting of nanoparticles in oncology. However, growing evidence indicates that the accumulation of nanomaterials via the EPR effect could be more efficient. Inspired by our clinical observation of the Gap Junction connecpion between folliculostellate cells and pituitary adenoma cells, we designed a novel drug delivery system that targets tumours by coating folliculostellate cell (FS) membranes onto PLGA nanoparticles (NPs). The resulting FSNPs, inheriting membrane proteins from the folliculostellate cell membrane, significantly enhanced the EPR effect compared to nanoparticles without cancer cell membranes. We further demonstrated that mitotane encapsulation improved the therapeutic efficacy of mitotane in both heterotopic and orthotopic pituitary adenoma models. Owing to its significant efficacy, our FS cell membrane-coated nanoplatforms has the potential to be translated into clinical applications for the treatment of invasive pituitary adenoma.
MicroRNA-30d Target TIMP3 Induces Pituitary Tumor Cell Growth and Invasion.

Bowen Sun,Congxin Dai,Shangfeng Zhao,Hao Dong,Haocheng Liu,Yong Li,Renzhi Wang,Jun Kang

DOI: https://doi.org/10.21037/gs-21-720

2021-01-01

Gland Surgery

Abstract:BACKGROUND:As one of the most common intracranial tumors, pituitary adenomas, especially the Cushing's disease subtype, have been studied for many years. However, at present, effective methods for the early diagnosis of pituitary adenomas are very limited, especially for subtypes such as Cushing's disease. Therefore, it is of urgent importance to find effective molecular targets to develop new diagnostic and therapeutic methods for pituitary adenomas.METHODS:We showed the abnormally high expression of miR-30d in pituitary adenomas by analyzing data in the Gene Expression Omnibus (GEO) database and revealed a novel molecular mechanism of miR-30d in regulating the proliferation and invasion of a pituitary adenoma cell line (AtT-20). Cell culture and transfection, and RNA interference (RNAi) were used to treat AtT-20 cells to test the effects of miR-30d and TIMP3 on cells. Quantitative polymerase chain reaction (qPCR) was used to determine the messenger RNA (mRNA) expressions. We used 3-(4,5-diphenyltetrazolium bromide) (MTT) to determine cell viabilities. An invasion assay was performed using Transwell chambers. Luciferase activity was tested with a dual-luciferase assay.RESULTS:We found that the expression of miR-30d in pituitary adenoma was higher than that in normal pituitary tissues. It was revealed that miR-30d promoted the proliferation and invasion of AtT-20 cells by inhibiting the expression of TIMP3. In the above process, miR-30d could bind to the 3'-untranslated region (3'-UTR) of TIMP3 mRNA.CONCLUSIONS:The mir-30d/TIMP3 signaling pathway plays an important regulatory role in pituitary adenomas. These new discoveries may reveal more functions of miR-30d and lay the foundation for future clinical development of new drug targets.
The Experimental Study of Mirna in Pituitary Adenomas.

Siquan Liang,Li Chen,Huiling Huang,Dashi Zhi

DOI: https://doi.org/10.5137/1019-5149.jtn.7425-12.1

2013-01-01

Abstract:AIM:We investigated the differential miRNA expression in pituitary adenomas (both non-functioning and gonadotropin-secreting) and normal pituitaries.MATERIAL AND METHODS:RNA was extracted and purified from pituitary adenomas (10 non-functioning and 10 gonadotropin-secreting) and from two normal pituitary tissue samples. The samples were analyzed by miRNA microarray. Gene expression was measured using realtime RT-PCR with SYBR GREEN I.RESULTS:In non-functioning pituitary adenomas, 25 miRNA genes were up-regulated (six by over 5-fold) and 15 were down-regulated (six by more than 10-fold). miR-124a was the most up-regulated gene (38.58-fold), and miR-31 the most down-regulated gene (21.5-fold). In gonadotropin-secreting pituitary adenomas, 16 miRNA genes were up-regulated (six by over 4-fold) and 13 were down-regulated (seven by more than 10-fold). miR-10b was the most up-regulated gene (48.73-fold), and miR-503 the most down-regulated gene (39.8-fold). Five genes were up-regulated in both subtypes: miR-523, miR-10b, miR-520b, miR-422a, and miR-422b. The RT-PCR results were consistent with those of the gene chips.CONCLUSION:We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas.
Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma

Wentao Wu,Lei Cao,Yanfei Jia,Youchao Xiao,Xu Zhang,Songbai Gui

DOI: https://doi.org/10.3390/cells11182920

IF: 6

2022-09-20

Cells

Abstract:Pituitary adenoma (PA) is a common intracranial tumor without specific biomarkers for diagnosis and treatment. Non-coding RNAs (ncRNAs), including microRNAs (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA), regulate a variety of cellular processes, such as cell proliferation, differentiation, and apoptosis. Increasing studies have shown that the dysregulation of ncRNAs, especially the cross-talk between lncRNA/circRNA and miRNA, is related to the pathogenesis, diagnosis, and prognosis of PA. Therefore, ncRNAs can be considered as promising biomarkers for PA. In this review, we summarize the roles of ncRNAs from different specimens (i.e., tissues, biofluids, cells, and exosomes) in multiple subtypes of PA and highlight important advances in understanding the contribution of the cross-talk between ncRNAs (e.g., competing endogenous RNAs) to PA disease.

cell biology
The emerging role of miRNAs in pituitary adenomas: From molecular signatures to diagnostic potential

Ahmed S Doghish,Gharieb S El-Sayyad,Sherif S Abdel Mageed,Mai A Abd-Elmawla,Al-Aliaa M Sallam,Manar Mohammed El Tabaa,Nehal I Rizk,Alaa Ashraf,Osama A Mohammed,Safwat Abdelhady Mangoura,Tohada M Al-Noshokaty,Mohamed Bakr Zaki,Walaa A El-Dakroury,Mahmoud A Elrebehy,Mustafa Ahmed Abdel-Reheim,Mohammed S Elballal,Ahmed I Abulsoud

DOI: https://doi.org/10.1016/j.yexcr.2024.114279

2024-10-01

Abstract:Pituitary adenomas (PAs) are an array of tumors originating from the pituitary gland. PAs are sorted as functional or nonfunctional according to their hormonal activity and classified according to size into microadenomas and macroadenomas. Still, the cellular events that trigger the transformations in pituitary neoplasms are not fully understood, and the current classification methods do not precisely predict clinical behavior. A rising number of researches have emphasized the role of miRNAs, that drawn more attention as oncogenic molecules or tumor suppressors. The etiopathological mechanisms of PAs include multiple molecular cascades that are influenced by different miRNAs. miRNAs control the cell cycle control, pro- or antiapoptotic processes, and tumor invasion and metastasis. miRNAs offer a novel perspective on tumor features and behaviors and might be valuable in prognostication and therapeutic plans. In pituitary adenomas, miRNAs showed a specific expression pattern depending on their size, cell origin, remission, and treatments. Screening miRNA expression patterns is promising to monitor and evaluate recurrence, as well as to investigate the efficacy of radiation and chemotherapy for PAs exhibiting aggressive behavior. Thus, the current review investigated the interplay of the miRNAs' pivotal role in offering new opportunities to translate these innovative epigenetic tools into healthcare applications.
Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention

Adel Mohamed Aboregela

DOI: https://doi.org/10.1007/s00210-024-03347-6

2024-08-05

Abstract:Pituitary adenomas (PAs) are tumors originating in the pituitary gland, a small gland located at the base of the brain. They are the most common type of pituitary tumor, affecting approximately 1 in 10 people over their lifetime. Common symptoms include headaches, vision problems, hormonal imbalances, and weight changes. Treatment options depend on the type and size of the adenoma and may consist of medication, surgery, radiation therapy, or a combination. PAs are typically benign and slow-growing, but they can cause significant health issues if left untreated. Proper diagnosis and management by an experienced multidisciplinary team is important for achieving the best outcomes. Natural compounds like celastrol, curcumin, quercetin, apigenin, resveratrol, epigallocatechin gallate (EGCG), and genistein have shown the ability to inhibit cell growth, promote cell death, and suppress hormone activity in pituitary tumor cells, suggesting their potential as alternative or complementary treatments for PAs. MicroRNAs (miRNAs) are a kind of tiny RNA molecules that do not code for proteins and have a vital function in controlling gene expression. These 21-23 nucleotide-long molecules regulate gene expression by binding to complementary sequences in mRNA molecules, leading to mRNA degradation. miRNAs participate in a wide range of biological activities, including apoptosis, metastasis, differentiation, and proliferation. The research indicates that miRNAs play a crucial role in the pathogenesis, therapeutic approaches, diagnosis, and prognosis of PAs. This review article will provide a comprehensive analysis of the current understanding of the efficacy of naturally derived anti-cancer agents in the treatment of PAs. Furthermore, the study provides a comprehensive assessment of the miRNAs in PAs, their role in the development of PAs, and their potential application in the treatment of the condition.
Research status and prospects of pituitary adenomas in conjunction with neurological and psychiatric disorders and the tumor microenvironment

Siyuan Cui,Sainan Chen,Xuechao Wu,Qing Wang

DOI: https://doi.org/10.3389/fnins.2024.1294417

IF: 4.3

2024-04-23

Frontiers in Neuroscience

Abstract:Patients with pituitary neuroendocrine tumors (PitNETs) often experience neuropsychiatric disorders due to factors such as hormonal imbalances, and inadequate management of medications, surgeries, and radiation therapies. Commonly observed disorders include depression, anxiety, and cognitive dysfunction, which significantly impact patients' quality of life and prognosis. PitNETs have a significant presence of immune cells within the tumor microenvironment (TME), predominantly macrophages and T lymphocytes. These immune cells secrete a variety of cytokines, growth factors, and chemokines, which regulate the biological behaviors of PitNETs, including tumor initiation, proliferation, migration, invasion, and angiogenesis. In addition, this review provides a pioneering summary of the close relationships between the aberrant secretion of proinflammatory cytokines within the TME of PitNETs and the occurrence of neuropsychiatric disorders, along with their potential underlying mechanisms. The cytokines produced as a result of TME dysregulation may affect various aspects of the central nervous system, including neurotransmitter metabolism, neuroendocrine function, and neurovascular plasticity, thereby leading to a higher susceptibility to neurobehavioral disorders in PitNET patients.

neurosciences
MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN

Kai Zhou,Tingrong Zhang,YanDong Fan,Serick,Guojia Du,Pengfei Wu,Dangmurenjiafu Geng

DOI: https://doi.org/10.1007/s13277-016-5155-2

2016-07-27

Tumor Biology

Abstract:The purpose of this study was to investigate the expression of microRNA-106b (miR-106b) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) in pituitary tumor and to confirm whether miR-106b promotes proliferation and invasion of pituitary tumor cells through the PI3K/AKT signaling pathway by targeted regulation of PTEN expression, and thereby to find new targets for the treatment of pituitary tumor. Fifty-five cases of pituitary tumor tissue samples were collected, including 29 cases of invasive pituitary tumor, non-invasive 26 cases, and 8 normal pituitaries. The expression level of miR-106b in pituitary tumor tissue was detected by quantitative real-time PCR, and the expression of PTEN protein was detected by immunohistochemistry. PTEN 3′-untranslated region (UTR) luciferase vector was constructed, and dual-luciferase reporter gene assay was employed to examine the effect of miR-106b on PTEN 3′-UTR luciferase activity. AtT-20 cells were transfected with miR-106b mimics, miR-106b inhibitor, PTEN expression plasmid, and miR-106b mimics + PTEN expression plasmid respectively, and the changes in cellular proliferation and invasion were observed via MTT method and transwell assay respectively. PTEN messenger RNA (mRNA) expression was determined by quantitative real-time PCR, and western blotting was performed to detect the expression of PTEN, PI3K, AKT, and pAKT. miR-106b showed up-regulation in invasive pituitary tumor tissue: the expression level was significantly up-regulated compared with normal tissues and the non-invasive pituitary tumor tissue (P < 0.05). The positive rate of PTEN protein expression in invasive pituitary tumor tissues was significantly lower than in normal and non-invasive tissues (P < 0.01). Dual-luciferase reporter gene assay showed that miR-106b could bind to the 3ʹ-UTR of PTEN specifically and significantly inhibited the luciferase activity, cutting the 46 % (P < 0.01). Down-regulation of miR-106b or up-regulation of PTEN could suppress cell proliferation and invasion of AtT-20 cells, and PTEN expression plasmid could partially simulate the function of miR-106b. Expression of PTEN mRNA and protein decreased significantly in AtT-20 cells overexpressing miR-106b. The expression levels of PI3K and p-AKT were significantly inhibited by miR-106b inhibitor and increased by miR-106b mimics. The expression of miR-106b showed up-regulation in pituitary tumor tissues, while the protein expression of PTEN presented opposite results. The findings of this study further demonstrated that miR-106b as an oncogene regulated the pituitary tumor cell proliferation and invasion in vitro by directly targeting PTEN through the PI3K/AKT signaling pathway. Our study suggests that miR-106b and PTEN are likely to serve as potential diagnostic biomarkers or therapeutic targets for pituitary tumor treatment in the future.
MiR-219a-2-3p suppresses cell proliferation and promotes apoptosis by targeting MDM2/p53 in pituitary adenomas cells

Yibiao Wang,Jiaonong Zhao,Chaocai Zhang,Pengcheng Wang,Chuixue Huang,Hao Peng

DOI: https://doi.org/10.1080/09168451.2020.1715780

Abstract:Pituitary adenomas constitute one of the most common intracranial tumors. MicroRNAs play an important role in development and progression of pituitary adenomas. In this study, we showed that miR-219a-2-3p was significantly down-regulated in pituitary adenomas cells. Overexpression of miR-219a-2-3p suppressed the proliferation and promoted apoptosis of pituitary adenomas cells. After bioinformatics analysis, we found that MDM2 was one of the downstream targets of miR-219a-2-3p. Further researches showed that miR-219a-2-3p could reduce the protein level of MDM2 by binding to the 3'-UTR of MDM2 and promoted p53 expression. Then, we overexpressed both miR-219a-2-3p and MDM2 in the same group and found that it could counteract the effect of overexpressing miR-219a-2-3p alone on proliferation and apoptosis of pituitary adenoma cells. Taken together, these results suggested that miR-219a-2-3p regulated the proliferation and apoptosis by targeting MDM2/p53 in pituitary adenomas. Therefore, miR-219a-2-3p may serve as a novel marker and therapeutic target for pituitary adenomas.
SDF-1 alpha/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth via Targeting VEGFA

Xiaoyu Wang,Yuanjian Fang,Yunxiang Zhou,Xiaoming Guo,Ke Xu,Chenguang Li,Jianmin Zhang,Yuan Hong

DOI: https://doi.org/10.3389/fendo.2020.566761

IF: 6.055

2020-01-01

Frontiers in Endocrinology

Abstract:Background Nonfunctioning pituitary neuroendocrine tumor (NF-PitNET) is difficult to resect. Except for surgery, there is no effective treatment for NF-PitNET. MicroRNA-134 (miR-134) has been reported to inhibit proliferation and invasion ability of tumor cells. Herein, the mechanism underlying the effect of miR-134 on alleviating NF-PitNET tumor cells growth is explored. Methods Mouse pituitary alpha T3-1 cells were transfected with miR-134 mimics and inhibitor, followed by treatment with stromal cell-derived factor-1 alpha (SDF-1 alpha) in vitro. MiR-134 expression level: we used quantitative real-time PCR (qRT-PCR) to detect the expression of miR-134. Cell behavior level: cell viability and invasion ability were assessed using a cell counting kit-8 (CCK8) assay and Transwell invasion assay respectively. Cytomolecular level: tumor cell proliferation was evaluated by Ki-67 staining; propidium iodide (PI) staining analyzed the effect of miR-134 on cell cycle arrest; western blot analysis and immunofluorescence staining evaluated tumor migration and invasive ability. Additionally, we collected 27 NF-PitNET tumor specimens and related clinical data. The specimens were subjected to qRT-PCR to obtain the relative miR-134 expression level of each specimen; linear regression analysis was used to analyze the miR-134 expression level in tumor specimens and the age of the NF-PitNET population, gender, tumor invasion, prognosis, and other indicators. Results In vitro experiment, miR-134 was observed to significantly inhibit alpha T3-1 cells proliferation characterized by inhibited cell viability and expressions of vascular endothelial growth factor A (VEGFA) and cell cycle transition from G1 to S phase (P < 0.01). VEGFA was verified as a target of miR-134. Additionally, miR-134-induced inhibition of alpha T3-1 cell proliferation and invasion was attenuated by SDF-1 alpha and VEGFA overexpression (P < 0.01). In primary NF-PitNET tumor analysis, miR-134 expression level was negatively correlated with tumor invasion (P = 0.003). Conclusion The regulation of the SDF-1 alpha/miR-134/VEGFA axis represents a novel mechanism in the pathogenesis of NF-PitNETs and may serve as a potential therapeutic target for the treatment of NF-PitNETs.
SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth via Targeting VEGFA

Xiaoyu Wang,Yuanjian Fang,Yunxiang Zhou,Xiaoming Guo,Ke Xu,Chenguang Li,Jianmin Zhang,Jianmin Zhang,Jianmin Zhang,Yuan Hong

DOI: https://doi.org/10.3389/fendo.2020.566761

IF: 6.055

2020-01-01

Frontiers in Endocrinology

Abstract:BackgroundNonfunctioning pituitary neuroendocrine tumor (NF-PitNET) is difficult to resect. Except for surgery, there is no effective treatment for NF-PitNET. MicroRNA-134 (miR-134) has been reported to inhibit proliferation and invasion ability of tumor cells. Herein, the mechanism underlying the effect of miR-134 on alleviating NF-PitNET tumor cells growth is explored.MethodsMouse pituitary αT3-1 cells were transfected with miR-134 mimics and inhibitor, followed by treatment with stromal cell-derived factor-1α (SDF-1α) in vitro. MiR-134 expression level: we used quantitative real-time PCR (qRT-PCR) to detect the expression of miR-134. Cell behavior level: cell viability and invasion ability were assessed using a cell counting kit-8 (CCK8) assay and Transwell invasion assay respectively. Cytomolecular level: tumor cell proliferation was evaluated by Ki-67 staining; propidium iodide (PI) staining analyzed the effect of miR-134 on cell cycle arrest; western blot analysis and immunofluorescence staining evaluated tumor migration and invasive ability. Additionally, we collected 27 NF-PitNET tumor specimens and related clinical data. The specimens were subjected to qRT-PCR to obtain the relative miR-134 expression level of each specimen; linear regression analysis was used to analyze the miR-134 expression level in tumor specimens and the age of the NF-PitNET population, gender, tumor invasion, prognosis, and other indicators.ResultsIn vitro experiment, miR-134 was observed to significantly inhibit αT3-1 cells proliferation characterized by inhibited cell viability and expressions of vascular endothelial growth factor A (VEGFA) and cell cycle transition from G1 to S phase (P < 0.01). VEGFA was verified as a target of miR-134. Additionally, miR-134-induced inhibition of αT3-1 cell proliferation and invasion was attenuated by SDF-1α and VEGFA overexpression (P < 0.01). In primary NF-PitNET tumor analysis, miR-134 expression level was negatively correlated with tumor invasion (P = 0.003).ConclusionThe regulation of the SDF-1α/miR-134/VEGFA axis represents a novel mechanism in the pathogenesis of NF-PitNETs and may serve as a potential therapeutic target for the treatment of NF-PitNETs.
Dysregulated miR-137 and its target EGFR contribute to the progression of pituitary adenomas

Dong Wei,Zhang Yu,Yue Cheng,Huang Jiawei,Gao Jian,Gao Hua,Dong Guilan

DOI: https://doi.org/10.1016/j.mce.2020.111083

IF: 4.369

2021-01-01

Molecular and Cellular Endocrinology

Abstract:<p>Pituitary adenomas (PAs) hypersecrete hormones or cause mass effect symptoms, with 10%–35% patients showing resistance to standard therapies. Targeting epidermal growth factor receptor (EGFR) has significantly improved the clinical outcome in many cancers. In this study, immunochemistry results showed that EGFR associated H-scores in 116 PA samples were higher than those in pituitary glands, and that p21, p27-and Wif-1 associated H-scores were lower (<em>P</em> < 0.05 for all). Patients with high levels of EGFR had increased PA invasion, lower total resection, and lower p21 and p27 expression than those with low levels of EGFR expression. Dual-luciferase reporter gene assays showed that EGFR was the target gene of miR-137, and miR-137 mimic could inhibit the cell proliferation of GH3 cells and induce apoptosis and G1-phase arrest of GH3 cells. A combination of miR-137 mimic and AZD9291 had stronger inhibition on GH3 cells compared with miR-137 mimic or AZD9291 alone; furthermore, miR-137 inhibitor partially reversed the inhibition of AZD9291. p21 and p27 were shown to be involved in the miR-137- and AZD9291-mediated effects on GH3 cells. In all, activation of EGFR in PAs was related to tumor invasive behavior, which reduced the total resection of PAs in patients. A combination of miR-137 and AZD9291 provided a potential treatment for PAs, especially for patients who show resistance to standard treatment.</p>

cell biology,endocrinology & metabolism
Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas Were Identified by Using Analysis of Micrornas Expression Profile

Silin Wu,Ye Gu,Yuying Huang,Tyh-Chai Wong,Hailin Ding,Tengfei Liu,Yu Zhang,Xiaobiao Zhang

DOI: https://doi.org/10.1007/s10528-017-9794-9

2017-01-01

Biochemical Genetics

Abstract:The microRNAs (miRNAs) are involved in multiple pathological processes among various types of tumors. However, the functions of miRNAs in benign brain tumors are largely unexplored. In order to explore the pathogenesis of the invasiveness in non-functional pituitary adenoma (NFPA), the miRNAs expression profile was analyzed between invasive and non-invasive non-functional pituitary adenoma by miRNAs microarray. Six most significant differentially expressed miRNAs were identified including four upregulated miRNAs hsa-miR-181b-5p, hsa-miR-181d, hsa-miR-191-3p, and hsa-miR-598 and two downregulated miRNAs hsa-miR-3676-5p and hsa-miR-383. The functions and corresponding signaling pathways of differentially expressed miRNAs were investigated by bioinformatics techniques, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The result of GO analysis indicates regulation of voltage-gated potassium channel activity, positive regulation of sodium ion transport, positive regulation of GTPase activity, negative regulation of Notch signaling pathway, etc. KEGG pathway reveals a series of biological processes, including prolactin signaling pathway, endocrine and other factor-regulated calcium reabsorption, fatty acid metabolism, neuroactive ligand-receptor interaction, etc. The miRNAs hsa-miR-181a-5p was verified by quantitative real-time PCR, and the expression level was in accordance with the microarray result. Our result can provide the evidence on featured miRNAs which play a prominent role in pituitary adenoma as effective biomarkers and therapeutic targets in the future.
MicroRNA-524-5p Functions As a Tumor Suppressor in a Human Pituitary Tumor-Derived Cell Line.

Wang Zhen,Du Qiu,Chen Zhiyong,Wang Xin,Jian Mengyao,Zhu Dimin,Hu Chonghui,Wang Haijun,Zhu Yonghong

DOI: https://doi.org/10.1055/s-0043-106437

2017-01-01

Hormone and Metabolic Research

Abstract:AbstractClinical nonfunctional pituitary adenomas (NFAs) account for about 40% of pituitary adenomas with almost no clinically relevant hormonal symptoms. Increasing evidence shows that many microRNAs are involved in the development and progression of pituitary adenomas. MicroRNA-524-5p (miR-524-5p) has been reported to cause characteristic alterations in various tumors. However, the functional importance of miR-524-5p in NFAs remains unknown. The aim of this study was to explore the effects of overexpressing miR-524-5p on the proliferation, migration, invasion, and tumorigenicity of pituitary-derived folliculostellate (PDFS) cells using lentiviral transfection. Interestingly, the results showed that overexpressing miR-524-5p downregulated pituitary tumor-transforming gene 1 (PTTG1) binding factor (PBF) expression at both mRNA and protein levels and significantly attenuated cell proliferation, clonogenicity, migration, and invasion in vitro. Moreover, enhancing miR-524-5p blocked tumor growth in a nude mouse xenograft model in vivo. These findings suggest that miR-524-5p appears to play a critical role in the regulation of biological properties of PDFS cells, and may represent a potential therapeutic target for NFAs.
The Gene Expression Profiles of Pituitary Adenomas Studied by Cdna Microarray

HU Ji,WANG Xuan-chun,Shen Ye,LI Shi-qi,WANG Yong-fei,WU Jing-song,Zhao Yao,Xu Bin,SHOU Xue-Fei,ZHANG Yu-lin,YU Mao-hua,HU Ren-ming

DOI: https://doi.org/10.3969/j.issn.1672-8467.2005.05.016

2005-01-01

Abstract:Purpose To screen differentially expressed gene profiles in pituitary adenomas,compare with that in normal pituitary,and to discuss the possible role of candidate genes in the pathogenesis of pituitary adenoma. Methods The differentially expressed genes in pituitary adenomas were studied by complementary DNA microarrays,and confirmed by RT-PCR and realtime-PCR. Results In comparison with that in normal pituitary,the genes involved in signal transduction pathway,growth and differentiation are mainly differentially expressed.PP4R2,GHRHR and clusterin are significantly highly expressed in prolactinoma,somatotroph and nonfunctioning adenomas respectively,which was also proved by RT-PCR and realtime-PCR. Conclusions PP4R2,GHRHR and clusterin may play a pivotal role in the development of prolactinoma,somatotroph and nonfunctioning adenomas respectively.
MicroRNAs: emerging driver of cancer perineural invasion

Mei Zhang,Hong-chun Xian,Li Dai,Ya-ling Tang,Xin-hua Liang

DOI: https://doi.org/10.1186/s13578-021-00630-4

2021-06-29

Abstract:Abstract The perineural invasion (PNI), which refers to tumor cells encroaching on nerve, is a clinical feature frequently occurred in various malignant tumors, and responsible for postoperative recurrence, metastasis and decreased survival. The pathogenesis of PNI switches from ‘low-resistance channel’ hypothesis to ‘mutual attraction’ theory between peripheral nerves and tumor cells in perineural niche. Among various molecules in perineural niche, microRNA (miRNA) as an emerging modulator of PNI through generating RNA-induced silencing complex (RISC) to orchestrate oncogene and anti-oncogene has aroused a wide attention. This article systematically reviewed the role of microRNA in PNI, promising to identify new biomarkers and offer cancer therapeutic targets.

biochemistry & molecular biology
Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors

Xiaopeng Guo,Yiying Yang,Zhihong Qian,Mengqi Chang,Yuanli Zhao,Wenbin Ma,Yu Wang,Bing Xing

DOI: https://doi.org/10.1016/j.canlet.2024.216908

IF: 9.756

2024-04-27

Cancer Letters

Abstract:Pituitary neuroendocrine tumors (pitNETs) are the second most common primary brain tumors. Despite their prevalence, the tumor immune microenvironment (TIME) and its clinical implications remain largely unexplored. This review provides a comprehensive overview of current knowledge on the immune landscape and advancements in targeted immunotherapy for pitNETs. Macrophages and T cells are principal immune infiltrates within the TIME. Different subtypes of pitNETs display distinct immune patterns, influencing tumor progressive behaviors. PD-L1, the most extensively studied immune checkpoint, is prominently expressed in hormonal pitNETs and correlates with tumor growth and invasion. Cytokines and chemokines including interleukins, CCLs, and CXCLs have complex correlations with tumor subtypes and immune cell infiltration. Crosstalk between macrophages and pitNET cells highlights bidirectional regulatory roles, suggesting potential macrophage-targeted strategies. Recent preclinical studies have demonstrated the efficacy of anti-PD-L1 therapy in a mouse model of corticotroph pitNET. Moreover, anti-PD-1 and/or anti-CTLA-4 immunotherapy has been applied globally in 28 cases of refractory pitNETs, showing more favorable responses in pituitary carcinomas than aggressive pitNETs. In conclusion, the TIME of pitNETs represents a promising avenue for targeted immunotherapy and warrants further investigation.

oncology
Tumour microenvironment and pituitary tumour behaviour

P. Marques,M. Korbonits

DOI: https://doi.org/10.1007/s40618-023-02089-1

2023-04-15

Journal of Endocrinological Investigation

Abstract:The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like cytokines, chemokines and growth factors, which surround the tumour cells and may influence pituitary tumour behaviour and tumourigenic mechanisms. Recently, there has been intensive research activity in this field describing various pituitary tumour-infiltrating immune and stromal cell subpopulations, and immune- and microenvironment-related pathways. Key changes in oncological therapeutic avenues resulted in the recognition of pituitary as a target of adverse events for patients treated with immune checkpoint regulators. However, these phenomena can be turned into therapeutic advantage in severe cases of pituitary tumours. Therefore, unravelling the pituitary tumour microenvironment will allow a better understanding of the biology and behaviour of pituitary tumours and may provide further developments in terms of diagnosis and management of patients with aggressively growing or recurrent pituitary tumours.

endocrinology & metabolism
Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling

Liang Lyu,Yong Jiang,Weichao Ma,Haiyan Li,Xiaoling Liu,Li Li,Ao Shen,Yang Yu,Shu Jiang,Huihui Li,Peizhi Zhou,Senlin Yin

DOI: https://doi.org/10.1038/s41416-022-02126-5

2023-01-12

BJC Reports

Abstract:PIT1-positive pituitary adenoma (PIT1-PA) is one of the most important lineages of pituitary adenoma (PA), which causes systematic endocrine disorders and a worse prognosis. Tumour-associated fibroblast (TAF) is a crucial stroma cell type in the tumour microenvironment (TME). However, cellular and functional heterogeneity of TAF and immune cells in PIT1-PA have not been fully investigated.

MicroRNAs and Target Genes in Pituitary Adenomas

IsolationThe role of microRNA in the diagnosis and treatment of pituitary adenomas

Enhanced EPR Effects by Tumour Stromal Cell Mimicking Nanoplatform on Invasive Pituitary Adenoma

MicroRNA-30d Target TIMP3 Induces Pituitary Tumor Cell Growth and Invasion.

The Experimental Study of Mirna in Pituitary Adenomas.

Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma

The emerging role of miRNAs in pituitary adenomas: From molecular signatures to diagnostic potential

Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention

Research status and prospects of pituitary adenomas in conjunction with neurological and psychiatric disorders and the tumor microenvironment

MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN

MiR-219a-2-3p suppresses cell proliferation and promotes apoptosis by targeting MDM2/p53 in pituitary adenomas cells

SDF-1 alpha/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth via Targeting VEGFA

SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth via Targeting VEGFA

Dysregulated miR-137 and its target EGFR contribute to the progression of pituitary adenomas

Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas Were Identified by Using Analysis of Micrornas Expression Profile

MicroRNA-524-5p Functions As a Tumor Suppressor in a Human Pituitary Tumor-Derived Cell Line.

The Gene Expression Profiles of Pituitary Adenomas Studied by Cdna Microarray

MicroRNAs: emerging driver of cancer perineural invasion

Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors

Tumour microenvironment and pituitary tumour behaviour

Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling